Published in Vopr Onkol on January 01, 2010
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. Colorectal Dis (2013) 1.39
[Estrogen receptor expression in tumors different from breast cancer]. Antibiot Khimioter (2009) 0.86
[Radio- and thermoradiotherapy of patients with aggressive fibromatosis]. Vopr Onkol (1999) 0.77
[Thermoradiotherapy as a component of desmoid tumor management: 10-year experience]. Vopr Onkol (2005) 0.77
[Radiation treatment of bladder cancer using different fractionation regimens]. Med Radiol (Mosk) (1991) 0.76
[HERV-K-associated carcinogenesis: co-expression of viral and cellular proteins in the development of human germ-cell tumors]. Vopr Virusol (2009) 0.76
[Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer]. Vopr Onkol (2015) 0.76
[Docetaxel in the treatment of metastatic gastric cancer]. Vestn Ross Akad Med Nauk (2009) 0.75
[Successes in the treatment of patients with disseminated testicular tumors of germ-cell origin]. Eksp Klin Farmakol (1995) 0.75
[Problems of radiotherapy for locally advanced prostate neoplasms]. Vopr Onkol (1999) 0.75
[Results of rotational gamma teletherapy of prostatic cancer]. Vopr Onkol (1982) 0.75
[The thermoradiotherapy of malignant salivary gland tumors]. Med Radiol (Mosk) (1991) 0.75
[Discordance of estrogen receptor status between primary and metastatic breast cancer--possible reasons and prognostic value]. Antibiot Khimioter (2013) 0.75
[Choice of the optimal variant of plastic surgery in head and neck tumors]. Vopr Onkol (1998) 0.75
[Combined treatment for rectal cancer using different radiomodification means]. Vopr Onkol (2008) 0.75
[Estrogen receptors beta--new target in cellular lung cancer treatment]. Vestn Ross Akad Med Nauk (2012) 0.75
[Computer tomography in topometric irradiation planning in prostate cancer]. Radiobiol Radiother (Berl) (1983) 0.75
[Advances in radiotherapy of malignant tumours]. Vestn Ross Akad Med Nauk (2011) 0.75
[Current procedure for treating testicular germ-cell tumors]. Urol Nefrol (Mosk) (1996) 0.75
[Radioisotope teletherapy of prostatic cancer]. Urol Nefrol (Mosk) (1980) 0.75
[Use of thermal radiochemotherapy in patients with anal epidermoid cancer]. Vestn Ross Akad Med Nauk (1996) 0.75
[Infusion of high doses of platidiam in the treatment of patients with germ cell testicular tumors]. Vopr Onkol (1990) 0.75
[Experience with conservative surgery for bone sarcoma involving major neurovascular bundles]. Vopr Onkol (2000) 0.75
[Conformal radiotherapy for prostate cancer]. Vopr Onkol (2010) 0.75
[Chemotherapy of disseminated germ cell tumors of the testis]. Sov Med (1987) 0.75
[Methods of topometric radiotherapy planning in prostate cancer]. Radiobiol Radiother (Berl) (1981) 0.75
[Bone marrow transplantation in oncology]. Vopr Onkol (1991) 0.75
[Treatment of patients with stage I nonseminomal germ cell testicular tumors]. Urol Nefrol (Mosk) (2002) 0.75
[Standard and hyperfractionated irradiation for locally advanced tumors (T3NOMO) of the larynx]. Vopr Onkol (1999) 0.75
[Radiotherapy as a component of treatment for Ewing's sarcoma]. Vopr Onkol (2005) 0.75
[Radiation pneumonitis in the treatment of early-stage breast cancer]. Vopr Onkol (2015) 0.75
[Thermoradiotherapy of rectal squamous cell cancer]. Sov Med (1987) 0.75
[Problems of dose fractionation in radiotherapy of patients with locally advanced esophageal cancer]. Vopr Onkol (1998) 0.75
[Conformal radiotherapy in nasopharyngeal cancer patients]. Vopr Onkol (2015) 0.75
[Status of radiotherapy of patients with cancer of the prostate]. Vestn Rentgenol Radiol (1988) 0.75
[Treatment of advanced ovarian cancer: results of the Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin RORC from 1993-2010]. Vestn Ross Akad Med Nauk (2011) 0.75
[The importance of DNA-cytometry for the prediction of nasopharyngeal malignancy]. Vestn Otorinolaringol (2011) 0.75
[Anti-VEGF therapy: clinical effectiveness, mechanism of antitumor action and resistance]. Vopr Onkol (2009) 0.75
[Prognosis and results of radiotherapy of esophageal cancer with the use of radiomodifiers]. Med Radiol (Mosk) (1989) 0.75
[The development of radiotherapeutic techniques at the beginning of the 21st century in Blokhin Russian Oncological Research Center of Russian Academy of Medical Sciences]. Vestn Ross Akad Med Nauk (2007) 0.75
[Cryoradiation therapy of the patients presenting with locally advanced auricular skin cancer]. Vestn Otorinolaringol (2012) 0.75
[Hyperthermia as a method for treating prostatic adenoma]. Urol Nefrol (Mosk) (1991) 0.75
[First experience with thermoradiochemotherapy for patients with squamous cell carcinoma of the anal canal]. Vopr Onkol (1996) 0.75
[Effectiveness of neoadjuvant chemoradiotherapy of locally advanced rectal cancer in conjunction with local hyperthermia and metronidazole]. Vopr Onkol (2011) 0.75
[The distribution of HLA genes in Russian patients with germ cell tumors]. Vestn Ross Akad Med Nauk (2007) 0.75
[Management and drug therapy of patients with disseminated testicular tumors]. Vopr Onkol (1986) 0.75
[Regional metastatic disease in oral SCC identified by preventive lymphatic nodes dissection]. Stomatologiia (Mosk) (2012) 0.75
[Comparative assessment of the five-year results of surgical, combined, radiation and chemoradiotherapy in laryngeal cancer (T3N0M0)]. Vopr Onkol (2006) 0.75
[Adjuvant radiotherapy in the combined treatment of rectal cancer]. Vopr Onkol (1998) 0.75
[The results of the use of bleomycin and its analogs in the VAB-6 protocol in treating testicular tumors]. Antibiot Khimioter (1988) 0.75
[Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer]. Mol Biol (Mosk) (2012) 0.75
[Oral SCC regional metastatic disease patterns revealed by preventive neck dissections]. Stomatologiia (Mosk) (2012) 0.75
[Results of surgical and radiotherapy of prostatic cancer T1-4N0-1M0]. Urologiia (2009) 0.75
[Raising qualifications and standards of knowledge of Russian undergraduate students and doctors in oncology]. Vopr Onkol (2008) 0.75
[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma]. Vopr Onkol (1996) 0.75
[The role of stereotactic radiotherapy in treatment of patients with metastatic lesion of lungs]. Vopr Onkol (2015) 0.75
[The prognostic significance of the rate of growth in the radiation treatment of esophageal cancer]. Med Radiol (Mosk) (1989) 0.75
[New antitumor preparations]. Vopr Onkol (1995) 0.75
[Results of complex treatment of patients with squamous cell carcinoma of the anal canal using advanced radiotherapy technologies]. Vopr Onkol (2015) 0.75
[Management of patients with seminoma, residual after induction chemotherapy, and disseminated in the retroperitoneal space]. Vopr Onkol (1999) 0.75
[The comparative efficacy of radiation and thermoradiation treatments in prostatic cancer]. Urol Nefrol (Mosk) (1996) 0.75
[Thermoradiotherapy in locally extensive soft tissue sarcoma]. Vopr Onkol (1996) 0.75
[Range of combined treatment of locally advanced skin cancer]. Vopr Onkol (2005) 0.75
[Results of chemotherapy in patients with disseminated testicular tumors]. Vopr Onkol (1990) 0.75
[Radiation therapy in the combined treatment of prostatic cancer patients]. Urol Nefrol (Mosk) (1987) 0.75
[Study of testicular cancer gene expression in samples of oral leukoplakia and squamous cell carcinoma of the mouth]. Vopr Onkol (2012) 0.75
[Present-day methods of treatment of early-stage Hodgkin's disease]. Vopr Onkol (2007) 0.75
[Method of gamma teletherapy in prostatic cancer]. Med Radiol (Mosk) (1983) 0.75
[Sentinel lymph nodes in squamous cell cancer of the head and neck]. Vestn Otorinolaringol (2007) 0.75
[Choosing combined or complex treatment approach in oral SCC patients]. Stomatologiia (Mosk) (2012) 0.75
[Problems of radiation therapy of patients with malignant tumors and modern ways of resolving them]. Vestn Ross Akad Med Nauk (2001) 0.75
[An assessment of the efficacy of preoperative radio- and thermoradiotherapy in treating rectal cancer]. Vopr Onkol (1992) 0.75
[Preoperative thermoradiotherapy in the combined treatment of rectal tumors is the inferior ampullar segmentŏ]. Vopr Onkol (1999) 0.75
[Thermoradiochemotherapy of inoperable soft-tissue sarcoma]. Vopr Onkol (2005) 0.75
[The current potentials and outlook for drug therapy in oncology]. Vopr Onkol (1995) 0.75
[Complex treatment of breast cancer patients with brain metastases]. Vopr Onkol (2015) 0.75
[Phase I clinical study of human leukocytic interferon II for injections]. Ter Arkh (1983) 0.75
[Clinical use of colony-stimulating factors]. Vestn Akad Med Nauk SSSR (1990) 0.75
[Overall preparation of prostate cancer patients for radiation therapy]. Vestn Rentgenol Radiol (1981) 0.75
[The role of stereotactic radiotherapy in the treatment of patients with liver metastases]. Vopr Onkol (2015) 0.75
[Germ cell tumors of the testis: current status and future progress]. Vestn Ross Akad Med Nauk (1995) 0.75
[Tamoxifen molecular targets different from estrogen receptors]. Antibiot Khimioter (2012) 0.75
[Polyradiomodification as component of combined treatment of rectal cancer: rationale and results]. Vopr Onkol (2010) 0.75
[Use of bleomycetin in malignant testicular tumors and the problem of studying bleomycin analogs]. Antibiotiki (1984) 0.75
[The chemotherapy of nonseminomatous testicular tumors]. Urol Nefrol (Mosk) (1996) 0.75
[Radiation exposure and local hyperthermia in the treatment of prostatic cancer]. Urol Nefrol (Mosk) (1991) 0.75
[Significance pf retroperitoneal lymphadenectomy in the treatment of disseminated germinogenic testicular tumors after induction chemotherapy]. Urologiia (2000) 0.75
[A comparison of two modalities of complex chemoradiotherapy for locally advanced nasopharyngeal carcinoma]. Vopr Onkol (2004) 0.75
[Antibodies to stuctural proteins of endogenous retrovirus of the HERV-K/HTDV family as markers of human germ cell tumors]. Vopr Virusol (2006) 0.75
[Restoration of speech function in oncological patients with maxillary defects]. Vestn Otorinolaringol (2009) 0.75
[First experience with hypothermia in radiotherapy for locally advanced skin cancer of the face]. Vopr Onkol (2000) 0.75
[Choice of first-line chemotherapy for advanced ovarian cancer]. Vopr Onkol (1999) 0.75
[First experience with continuous infusions of cytosar using a Soviet-made portable dosage apparatus DF-1]. Ter Arkh (1984) 0.75
[Current issues in the chemotherapy of malignant tumors. Taxol (paclitaxel), Taxoter]. Vopr Onkol (1994) 0.75